Cargando…

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis

BACKGROUND: The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/− ChT remains an open question, and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ljubicic, Lidija, Janzic, Urska, Unk, Mojca, Terglav, Ana Sophie, Mohorcic, Katja, Seiwerth, Fran, Bitar, Lela, Badovinac, Sonja, Plestina, Sanja, Korsic, Marta, Kukulj, Suzana, Samarzija, Miroslav, Jakopovic, Marko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476899/ https://www.ncbi.nlm.nih.gov/pubmed/37665737 http://dx.doi.org/10.2478/raon-2023-0040

Ejemplares similares

Immunotherapy for thymoma
por: Jakopovic, Marko, et al.
Publicado: (2020)

Neutrophil-to-lymphocyte Ratio can Predict Outcome in Extensive-stage Small Cell Lung Cancer
por: Drpa, Gordana, et al.
Publicado: (2020)

The Interplay of Lung Cancer, COVID-19, and Vaccines
por: Trivanović, Dragan, et al.
Publicado: (2022)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Real-world Outcomes, Treatment Patterns and T790M Testing Rates in Non-small Cell Lung Cancer Patients Treated with First-line First- or Second-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors from the Slovenian Cohort of the REFLECT Study
por: Turnsek, Nina, et al.
Publicado: (2022)

Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta
por: Vrdoljak, Eduard, et al.
Publicado: (2020)

The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia
por: Čerina, Dora, et al.
Publicado: (2023)

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
por: Janzic, Urska, et al.
Publicado: (2023)

Nintedanib treatment for bleomycin-induced lung injury - First report
por: Rnjak, Dina, et al.
Publicado: (2023)

Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio help identify patients with lung cancer, but do not differentiate between lung cancer subtypes
por: Nikolić, Igor, et al.
Publicado: (2016)

1615P Impact of the COVID-19 pandemic on diagnosing and treatment referrals of lung cancer patients: A single-centre experience
por: Janzic, U., et al.
Publicado: (2021)

Stress cardiomyopathy following acute ischemic stroke during flexible bronchoscopy: a rare sequence of complications
por: Badovinac, Sonja, et al.
Publicado: (2013)

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung
por: Janzic, Urska, et al.
Publicado: (2017)

Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda, Masayuki, et al.
Publicado: (2015)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Šutić, Maja, et al.
Publicado: (2021)

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
por: Korphaisarn, Krittiya, et al.
Publicado: (2021)

Trends in lung cancer incidence and mortality in Croatia, 1988 to 2008
por: Janković, Mateja, et al.
Publicado: (2012)

Tracheal complications of mechanical ventilation for COVID-19: a plot twist for survivors
por: Badovinac, Sonja, et al.
Publicado: (2023)

A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
por: Janzic, Urska, et al.
Publicado: (2023)

CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma
por: Šutić, Maja, et al.
Publicado: (2021)

Lung Abscess: An Early Complication of Lung Transplantation in a Patient with Cystic Fibrosis
por: Markelić, I., et al.
Publicado: (2017)

Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity
por: Yan, Shu, et al.
Publicado: (2023)

Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
por: Grohé, Christian, et al.
Publicado: (2022)

Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study
por: Reck, Martin, et al.
Publicado: (2018)

Trends in incidence of lung cancer in Croatia from 2001 to 2013: gender and regional differences
por: Siroglavić, Katarina-Josipa, et al.
Publicado: (2017)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
por: Bourne, Michael H., et al.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
por: Corrales, Luis, et al.
Publicado: (2017)

Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

Nintedanib—A case of treating concurrent idiopathic pulmonary fibrosis and non‐small cell lung cancer
por: Dabholkar, Shakti, et al.
Publicado: (2022)

Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series
por: Hochmair, Maximilian Johannes, et al.
Publicado: (2022)

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
por: NISHIJIMA, NOBUHIKO, et al.
Publicado: (2016)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild, Sacha I
Publicado: (2014)

Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis
por: Kai, Yoshiro, et al.
Publicado: (2021)

Safety of nintedanib before lung transplant: an Italian case series
por: Balestro, Elisabetta, et al.
Publicado: (2018)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1q1fuct491ta8s9ejdib0g4c8f